Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock, par value $0.0001 per share, from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.
Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock, par value $0.0001 per share, from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.